Vol. 5 No. 12 (2025)
Reimbursement Recommendations

Vanzacaftor-Tezacaftor-Deutivacaftor (Alyftrek)

decorative image of the issue cover

Published December 5, 2025

Key Messages

  • Canada’s Drug Agency (CDA-AMC) recommends that Alyftrek be reimbursed by public drug plans for the treatment of cystic fibrosis (CF) in patients aged 6 years or older who have at least one F508del mutation or another responsive mutation in the CFTR gene (identified in Table of this document), if certain conditions are met.
  • Alyftrek should only be covered to treat patients aged 6 years or older who have a confirmed diagnosis of CF with at least 1 of the eligible CFTR gene mutations.
  • Alyftrek should only be reimbursed if prescribed by specialists in the treatment of CF and if the cost of Alyftrek does not exceed the total cost of other triple-combination CFTR modulator therapies (e.g., elexacaftor-tezacaftor-ivacaftor [ELX-TEZ-IVA] [Trikafta]). Alyftrek should not be reimbursed in combination with other CFTR modulator therapies.